Advisory Alpha’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.03M | Buy |
42,927
+1,631
| +4% | +$42.7K | 0.03% | 213 |
|
|
2026
Q1 | $1.16M | Sell |
41,296
-494
| -1% | -$13.2K | 0.03% | 177 |
|
|
2025
Q4 | $1.04M | Buy |
41,790
+2,122
| +5% | +$53.5K | 0.03% | 188 |
|
|
2025
Q3 | $1.07M | Buy |
39,668
+3,882
| +11% | +$95.8K | 0.03% | 171 |
|
|
2025
Q2 | $867K | Buy |
35,786
+496
| +1% | +$11.6K | 0.03% | 180 |
|
|
2025
Q1 | $894K | Buy |
35,290
+9,963
| +39% | +$261K | 0.03% | 172 |
|
|
2024
Q4 | $672K | Sell |
25,327
-3,488
| -12% | -$94.6K | 0.02% | 190 |
|
|
2024
Q3 | $834K | Buy |
28,815
+810
| +3% | +$23.6K | 0.03% | 167 |
|
|
2024
Q2 | $784K | Sell |
28,005
-3,062
| -10% | -$84.3K | 0.03% | 169 |
|
|
2024
Q1 | $862K | Buy |
31,067
+737
| +2% | +$20.5K | 0.04% | 169 |
|
|
2023
Q4 | $873K | Buy |
30,330
+325
| +1% | +$9.82K | 0.04% | 154 |
|
|
2023
Q3 | $995K | Sell |
30,005
-2,146
| -7% | -$75.9K | 0.05% | 141 |
|
|
2023
Q2 | $1.18M | Buy |
32,151
+13,637
| +74% | +$531K | 0.06% | 140 |
|
|
2023
Q1 | $755K | Buy |
18,514
+1,234
| +7% | +$53.3K | 0.05% | 137 |
|
|
2022
Q4 | $885K | Sell |
17,280
-1,726
| -9% | -$82.8K | 0.06% | 114 |
|
|
2022
Q3 | $832K | Buy |
19,006
+645
| +4% | +$31.3K | 0.06% | 116 |
|
|
2022
Q2 | $963K | Buy |
18,361
+574
| +3% | +$29.3K | 0.07% | 98 |
|
|
2022
Q1 | $921K | Buy |
17,787
+690
| +4% | +$35.8K | 0.06% | 118 |
|
|
2021
Q4 | $1.01M | Buy |
17,097
+4,723
| +38% | +$234K | 0.06% | 120 |
|
|
2021
Q3 | $532K | Buy |
12,374
+4,632
| +60% | +$205K | 0.04% | 156 |
|
|
2021
Q2 | $303K | Sell |
7,742
-447
| -5% | -$17.4K | 0.02% | 158 |
|
|
2021
Q1 | $297K | Buy |
8,189
+899
| +12% | +$31.9K | 0.03% | 139 |
|
|
2020
Q4 | $268K | Sell |
7,290
-194
| -3% | -$7.12K | 0.05% | 85 |
|
|
2020
Q3 | $259K | Buy |
7,484
+828
| +12% | +$29K | 0.06% | 77 |
|
|
2020
Q2 | $242K | Sell |
6,656
-461
| -6% | -$15.7K | 0.05% | 98 |
|
|
2020
Q1 | $248K | Sell |
7,117
-386
| -5% | -$13.2K | 0.07% | 77 |
|
|
2019
Q4 | $281K | Buy |
7,503
+29
| +0.4% | +$1.03K | 0.07% | 111 |
|
|
2019
Q3 | $253K | Sell |
7,474
-260
| -3% | -$9.46K | 0.07% | 99 |
|
|
2019
Q2 | $314K | Sell |
7,734
-945
| -11% | -$37.5K | 0.1% | 80 |
|
|
2019
Q1 | $335K | Buy |
8,679
+322
| +4% | +$12.9K | 0.12% | 77 |
|
|
2018
Q4 | $330K | Buy |
+8,357
| New | +$347K | 0.16% | 65 |
|
Other funds holding PFE
Advisory Alpha's PFE Position: Q2 2026 in Review
Advisory Alpha increased its Pfizer (PFE) stake by 3.9% in Q2 2026, buying an estimated $42.7K and bringing the position to 42,927 shares worth $1.03M. The position accounts for 0.03% of the portfolio, ranked #213.
Advisory Alpha first reported a position in PFE in Q4 2018 and has held it in 31 quarters since. The position peaked at $1.18M in Q2 2023. 2,823 funds tracked by Wall St. Rank hold PFE as of Q2 2026.
- Advisory Alpha held 42,927 shares of Pfizer worth $1.03M as of Q2 2026.
- Advisory Alpha bought 1,631 Pfizer shares in Q2 2026, an estimated $42.7K.
- Pfizer made up 0.03% of Advisory Alpha's portfolio in Q2 2026, its #213 holding.
- Advisory Alpha first reported a position in Pfizer in Q4 2018 and has held it in 31 quarters since.
- Advisory Alpha's Pfizer position peaked at $1.18M in Q2 2023.
- 2,823 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.
Based on Advisory Alpha's 13F filing for Q2 2026, filed 11 Aug 2026.